Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call Transcript

Page 8 of 8

So we’re really excited about this program.

Grant Pickering: And I think from a competitive standpoint, Joe, it’s not as active as certainly in the PCV space, as Jim — we comment on that.

Jim Wassil: Yes, there’s minimal activity. There is only a few academic centers and one pharma company that are currently looking at a Group A Strep vaccine. So minimal competitive environment as well.

Joseph Stringer: Great. Thank you for taking our questions.

Operator: Thank you. And ladies and gentlemen, it appears we have no further questions today. So, that will conclude today’s Vaxcyte fourth quarter and full-year 2023 earnings conference call. Please disconnect your line at this time and have a wonderful day. Thanks for joining, everyone.

Follow Vaxcyte Inc. (NASDAQ:PCVX)

Page 8 of 8